Status:

COMPLETED

All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Lead Sponsor:

University of Ulm

Conditions:

Acute Myeloid Leukemia

Eligibility:

All Genders

61+ years

Phase:

PHASE3

Brief Summary

This is a study looking at all-trans retinoic acid in combination with standard induction and consolidation therapy in older patients with newly diagnosed acute myeloid leukemia (AML).

Detailed Description

First Induction Therapy: * Cytarabine 100 mg/m² cont. i.v. days 1-5 * Idarubicin 12 mg/m² i.v. days 1, 3 * ATRA 45 mg/m² p.o. days 4-6, ATRA 15 mg/m² p.o. days 7-28 Second Induction Therapy: * C...

Eligibility Criteria

Inclusion

  • Newly diagnosed AML defined according to the World Health Organization (WHO) classification (excluding acute promyelocytic leukemia \[APL\])
  • Aged \> 60 years
  • All patients have to be informed about the character of the study. Written informed consent of each patient at study entry.
  • Molecular and cytogenetical analyses on initial bone marrow and peripheral blood specimen have to be performed at the central reference laboratories.

Exclusion

  • Bleeding independent of the AML
  • Acute promyelocytic leukemia
  • Uncontrolled infection
  • Participation in a concurrent clinical study
  • Insufficiency of the kidneys (creatinine \> 1.5 x upper normal serum level), of the liver (bilirubin, AST or AP \> 2 x upper normal serum level), severe obstruction or restrictive ventilation disorder, heart failure New York Heart Association \[NYHA\] III/IV
  • Severe neurological or psychiatric disorder interfering with ability of giving informed consent
  • No consent for the registration, storage and processing of data concerning the characteristics of the AML and the individual course
  • Performance status WHO \> 2

Key Trial Info

Start Date :

June 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2011

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT00151255

Start Date

June 1 2004

End Date

January 1 2011

Last Update

April 19 2017

Active Locations (29)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (29 locations)

1

Department of Hematology/Oncology, University Hospital of Innsbruck

Innsbruck, Austria, 6020

2

Department of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern

Linz, Austria, 4010

3

Medical Department III, St. Johann Hospital

Salzburg, Austria, 5020

4

Center of hematology and oncology, Hanusch Hospital

Vienna, Austria, 1140